Suppr超能文献

动脉调转术后晚期并发症的发生率和危险因素。

Incidence and risk factors for late complications after the arterial switch operation.

机构信息

Department of Cardiac Surgery, National Children's Medical Center, Beijing Children's Hospital, Capital Medical University, Beijing, China.

出版信息

J Card Surg. 2022 Oct;37(10):3117-3132. doi: 10.1111/jocs.16745. Epub 2022 Jul 5.

Abstract

OBJECTIVE

The purpose of this study was to evaluate our institution's 16-year arterial switch operation (ASO) experience and to determine early and late mortality and late morbidity, as well as the need for reoperation and catheter intervention, and finally, to explore risk factors for late complications and reintervention.

METHODS

The clinical data of 185 transposition of the great arteries (TGA) patients who received ASO treatment in our center from January 2006 to January 2022 were continuously included for retrospective study.

RESULTS

There were 13 early deaths (7.03%), 5 late deaths (3.01%), and 6 lost to follow-up. The median follow-up time for the 166 hospitalized survivors was 88.5 (2190) months. Moderate or above new aortic valve regurgitation (NAR; in this article, NAR represents moderate or greater reflux unless otherwise specified) occurred in 19 cases (11.45%), and aortic root dilation (ARD) occurred in 28 cases (16.87%). Late right ventricular outflow tract obstruction (RVOTO) occurred in 33 cases (19.88%). There were 18 patients (10.84%) who underwent late re-intervention, and the most common indication for intervention was RVOTO, followed by recurrent aortic coarctation in patients undergoing concurrent arch repair and NAR or ARD. Receiver operating characteristics analysis found that NAR had the strongest predictive power for ARD, followed by RVOTO, followed by bicuspid native pulmonary valve (BPV), and aorto-pulmonary diameter mismatch (APDMM) was the weakest. Multivariate analysis showed that APDMM, previous pulmonary artery banding (PAB), and mild NAR at discharge were independent risk factors for late NAR and ARD. Low surgical weight was an independent risk factor specific to NAR, and BPV was an independent risk factor specific to ARD. Older surgical age and ARD were independent risk factors for late RVOTO. Older surgical age, operation before 2014, late RVOTO, and late ARD were independent risk factors for late intervention. No reintervention events for coronary dysfunction were found in the late stage, but one patient occurred myocardial infarction due to coronary embolism after reoperation.

CONCLUSION

Early and late survival rates after ASO in TGA patients have been remarkably improved in recent decades. Increased rates of NAR, ARD, recurrent coarctation of the aorta, and RVOTO as children age are major future outcomes of concern and may imply more late reinterventions. Careful follow-up of neo-aortic valve and root function is imperative, especially in patients with APDMM, previous PAB, mild NAR at discharge, low surgical weight, and BPV structures.

摘要

目的

本研究旨在评估我院 16 年的动脉调转术(ASO)经验,确定早期和晚期死亡率及晚期发病率,以及再次手术和导管介入的需求,并最终探讨晚期并发症和再次干预的危险因素。

方法

连续纳入 2006 年 1 月至 2022 年 1 月在我院接受 ASO 治疗的 185 例完全性大动脉转位(TGA)患者的临床资料进行回顾性研究。

结果

早期死亡 13 例(7.03%),晚期死亡 5 例(3.01%),失访 6 例。166 例住院幸存者的中位随访时间为 88.5(2190)个月。19 例(11.45%)出现中重度以上新主动脉瓣反流(NAR;本文中除非另有说明,否则 NAR 代表中度或以上反流),28 例(16.87%)出现主动脉根部扩张(ARD)。晚期右心室流出道梗阻(RVOTO)发生 33 例(19.88%)。18 例(10.84%)患者行晚期再次介入治疗,最常见的介入指征为 RVOTO,其次为同期弓部修复合并 ARD、NAR 或 ARD 后再次发生的主动脉缩窄。受试者工作特征(ROC)曲线分析发现,NAR 对 ARD 的预测能力最强,其次是 RVOTO,再次是二叶式主动脉瓣(BPV),而主动脉-肺动脉直径不匹配(APDMM)的预测能力最弱。多因素分析显示,APDMM、既往肺动脉带环术(PAB)和出院时轻度 NAR 是晚期 NAR 和 ARD 的独立危险因素。低手术体重是 NAR 的独立危险因素,BPV 是 ARD 的独立危险因素。手术年龄较大是 RVOTO 的独立危险因素。手术年龄较大、2014 年前手术、晚期 RVOTO 和晚期 ARD 是晚期干预的独立危险因素。晚期未发现冠状动脉功能障碍的再介入事件,但 1 例患者在再次手术后发生了冠状动脉栓塞导致的心肌梗死。

结论

近几十年来,TGA 患者 ASO 后的早期和晚期生存率显著提高。随着儿童年龄的增长,NAR、ARD、复发性主动脉缩窄和 RVOTO 的发生率增加是主要的远期预后问题,可能需要更多的晚期再次介入治疗。仔细随访新主动脉瓣和根部功能至关重要,特别是在 APDMM、既往 PAB、出院时轻度 NAR、低手术体重和 BPV 结构的患者中。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验